KONEXBiotech & Pharma456190

Curachem

₩7,000 0.00%2026-11-18 close
Market Cap
₩12.8B
Turnover
₩0
Volume
0 shares
Shares out.
1.8M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Scale Limits at a Sole Domestic Radiolabeling Provider

Curachem holds a distinct position as the only domestic synthesizer of radiolabeled compounds, but its revenue scale and isotope sourcing remain constraints.

  1. 1

    As the only domestic radiolabeled compound synthesizer, it links directly to demand for ADME testing.

  2. 2

    Aggregated 2025 data show revenue of KRW 7.44B and net income of KRW 1.35B, indicating a profitable structure.

  3. 3

    Per 2023 DART filings, revenue rose while operating and net income fell, with higher SG&A cited as the cause.

  4. 4

    Dependence on overseas suppliers for 14C feedstock has been flagged as a supply risk.

  5. 5

    The current ratio fell from 608.3% in 2023 to 115.1% in 2025.

02

Business structure

Curachem was founded in 2009 and is a contract R&D company that synthesizes radiolabeled compounds using isotopes. The compounds, labeled with carbon-14 (14C) and tritium (3H), are used in absorption, distribution, metabolism and excretion (ADME) studies during drug development.

Disclosed revenue is concentrated in radiolabeled compound synthesis, and the experimental brokerage service line has generated no sales since 2021. Its customers are centered on multinational pharmaceutical companies in the United States and Europe.

Its trust-based relationships with Japanese drug developers have been described as a barrier that new entrants find difficult to overcome. In Korea, where domestic ADME evaluation providers were previously scarce, the company has been viewed as filling that gap.

A 2021 report said the company passed an EU GMP on-site audit by ICON, the global CRO formerly known as PRA, which supports its clinical trial material supply capability.

The business requires government licensing and biennial inspections for handling radioactive materials, yet its capital-light model means entry barriers are not considered high.

Compared with a large CDMO such as Samsung Biologics, its business model and scale differ markedly, and Curachem is a small specialist focused on research-grade labeled compounds. On the supply side, 14C depends on overseas reactor output, and a 2021 report cited this as a constraint on operations.

03

Recent trends

Per aggregated 2025 data, Curachem recorded revenue of KRW 7.44B, net income of KRW 1.35B and operating cash flow of KRW 359.65M. The same aggregation shows total assets of KRW 14.89B. Per 2023 DART filings, revenue rose 14.36% to KRW 6.88B.

Operating income fell 10.77% to KRW 960M and net income fell 12.96% to KRW 710M. The decline was attributed to SG&A rising to KRW 2.26B, and severance costs also increased by more than KRW 300M. The current ratio fell from 608.3% in 2023 to 129.2% in 2024 and 115.1% in 2025.

The share price hit an all-time low of KRW 6,790 on February 2, 2026, versus an all-time high of KRW 21,000 on June 13, 2024. Aggregated price data show a close of KRW 7,210 on June 30, 2026. The annual general meeting on March 26, 2026 approved all agenda items, including the 17th fiscal-year financial statements.

A June 13, 2026 report highlighted growing expectations around global CRO demand. As of 02:10 KST on November 11, 2026, the current price is KRW 7,210, with a 0.00% change and zero trading value.

04

Outlook

Future prospects hinge on three variables. The first is demand for radiolabeled compounds, which is linked to ADME studies extending from animal nonclinical work into early-phase human trials.

The second is isotope supply, where domestic 14C production would alter the current overseas allocation structure, according to the company's stated position. The third is the cost base, as the rise in SG&A and severance costs seen in 2023 will feed into future margins.

On growth, the gap between past targets and actual results is a reference point. During a 2013 funding round, the company projected 2016 revenue of KRW 28.7B, while 2022 revenue came in near KRW 6.0B. Entry into the clinical-material pharmaceutical market was also presented as a plan at that time.

Against 2025 revenue of KRW 7.44B, the pace of this expansion will serve as a benchmark for new business progress. On financing, the company previously raised KRW 2.5B in technology-valuation-based investment.

05

Bull factors

Sole domestic supplier status

Multiple reports describe Curachem as the only company in Korea focused on radiolabeled compound synthesis. A report also cites it as the sole provider of 3H labeled compound synthesis in Asia. A 2013 report noted that the DMPK segment of domestic preclinical testing has very few competitors. This position supports its role as a supplier as domestic drug development demand grows.

Global quality certification and CRO linkage

A 2021 report said Curachem passed an EU GMP on-site audit by ICON with favorable results. The audit is viewed as external recognition of its radiolabeled production facilities and quality control system for clinical trial materials. A June 2026 report also highlighted growing expectations around global CRO demand. Ties with large CROs are presented as a path to expanding overseas sales.

Profitable structure and cash flow

Aggregated data show Curachem posted net income of KRW 1.35B for 2025. Operating cash flow for the same year was also positive. Aggregated 2022 operating cash flow was about KRW 1.54B. The company has stayed out of loss territory, which supports business continuity.

06

Bear factors

Stagnant revenue scale

Annual revenue moved between roughly KRW 4.9B and KRW 6.5B from 2018 to 2022. A 2013 funding-stage projection of KRW 28.7B for 2016 revenue sits far above actual results. Even at KRW 7.44B for 2025, top-line growth appears limited. A single product line leaves less cushion against shifts in demand.

Overseas feedstock dependence and price pressure

After passing the ICON audit, the company ordered 70 curies but was allocated volume nearly identical to the prior year, according to a 2021 report. The same report described continued pressure from one-sided overseas allocation and repeated price increases as a threat to operations. These comments date from 2021, and current allocation terms are not well documented in available sources.

Rising costs and weaker liquidity

Operating income declined in 2023, and higher selling, general and administrative expenses were cited as the main reason. Severance costs also rose sharply, adding to labor-related cost burden. The current ratio fell from 608.3% in 2023 to 115.1% in 2025. A 2024 report put year-end 2023 cash at KRW 2.92B.

07

Risk factors

Macro

Biotech share prices tend to respond to external variables such as interest rates, exchange rates and overseas pharmaceutical demand. A recent report noted that life-science stocks have diverged according to earnings.

Because a large share of demand comes from overseas customers, exchange-rate and foreign demand swings can pass through to results.

Regulatory and licensing

Because the business handles radioactive isotopes, it requires government licensing and biennial inspections. Findings from an inspection could disrupt production or supply. Handling clinical-grade material also carries ongoing quality-system maintenance costs.

Liquidity

Curachem is listed on KONEX, where trading liquidity is generally limited. The current price of KRW 7,210 shows a 0.00% change with zero trading value, so the quoted price reflects little recent trading activity. At a market capitalization of KRW 13.2B, a small number of trades can move the price noticeably.

08

Overall view

Curachem holds a distinct position as Korea's only radiolabeled compound synthesizer, and its business is structurally tied to demand for ADME testing. Aggregated 2025 data show a profit, but revenue remains in the KRW 7 billion range.

The gap between its 2013 targets and actual results illustrates the difficulty of expanding the business. Overseas dependence for 14C feedstock, SG&A and severance burdens, and the decline in the current ratio remain the main weaknesses.

On the other side, passing the EU GMP audit and linkage to global CRO demand are cited as grounds for overseas supply growth. The quoted price of KRW 7,210 as of the June 30, 2026 close is shown with zero trading value at the reference time, which limits the reading of market valuation.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 12 more articles and sources
  1. prestocknews.com
  2. prestocknews.com
  3. financialfilings.com
  4. investing.com
  5. thevc.kr
  6. seenews365.com
  7. jbnews.com
  8. jbnews.com
  9. tradingview.com
  10. stockanalysis.com
  11. news.nate.com
  12. news2day.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis